CytoSorbents' Q4 2025 Review: Strong Sales Growth, Regulatory Progress, and PuriFi Expansion
CytoSorbents, a leading developer of blood purification technologies, has reported strong sales growth and significant regulatory progress in its fourth quarter and full year 2025 performance. According to the company's Q4 2025 conference call transcript, CytoSorbents' Chief Executive Officer, Dr. Phillip Chan, highlighted the key priorities achieved during the transitional year.
Dr. Chan noted that the company made measurable progress across four key priorities: driving sales growth outside of Germany, repositioning Germany for long-term success, building and leveraging a growing body of clinical evidence to support broader adoption, and advancing DrugSorb-ATR through the FDA regulatory process. The executive also emphasized the strengthening of the balance sheet and cost structure alignment to support a path to cash flow break-even.
On sales performance, CytoSorbents reported full-year 2025 sales revenues increased by 4% to $37.1 million, representing record core product sales. This growth was primarily driven by strong international market performance, with direct sales outside of Germany increasing by 13% to $8.6 million and distributor sales growing by 11.4% to $16.5 million. The company's focus on diversification highlighted the increasing strength in these channels, accounting for approximately 68% of total revenue.
However, German sales experienced a 10% decline to $11.8 million, which was attributed to near-term restructuring efforts aimed at building a more scalable and execution-driven commercial organization. Despite this, the company continued to demonstrate strong gross margins, reaching 71% for the full year and 74% in the fourth quarter, driven by manufacturing efficiencies.
Dr. Chan also discussed the progress of PuriFi, an important strategic initiative aimed at expanding access and utilization. The standalone hemoperfusion pump enables CytoSorb therapy to be delivered without reliance on existing dialysis infrastructure, allowing earlier intervention and expanding access in regions with limited dialysis infrastructure. Over 100 units have been placed globally, marking a significant milestone in the company's PuriFi expansion.
The executive expressed optimism regarding the early signs of improvement in the first quarter of 2026 from CytoSorbents' German team, including increased engagement and pipeline activity. This signals a gradual and sustained improvement over the course of the year, as the company continues to execute its strategic priorities and capitalize on new opportunities.
